Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements

Home/Pharma News | Posted 05/06/2024 post-comment0 Post your comment

In May 2024, Klinge Biopharma announced an exclusive licensing and supply agreement with MS Pharma for FYB203 commercialization in the MENA region. Previously, in April 2024, mAbxience and Teva Pharmaceuticals signed a strategic licensing agreement for a biosimilar candidate for oncology treatment.

Shaking hands V13D29

Klinge–MS Pharma
On 15 May 2024, it was announced that Klinge Biopharma, licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea (aflibercept), has entered into an exclusive licensing and supply agreement with MS Pharma for the commercialization of FYB203 in the MENA region.

MS Pharma is a leading regional pharmaceutical company in the MENA region. The company is also marketing Formycon’s ophthalmic Lucentis biosimilar FYB201 in the region.

Aflibercept is an ophthalmology product, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is a vascular endothelial growth factor (VEGF) inhibitor [1], a recombinant fusion protein consisting of human VEGF receptor 1 and VEGF receptor 2 extracellular domains fused to the Fc portion of human IgG1 which acts as a soluble decoy for the natural VEGF receptors that inhibits their activation, thereby reducing pathological angiogenesis. 

The FYB203 biosimilar underwent clinical trials that ended in 2023. Klinge also entered into a partnership with Coherus BioSciences for commercialization of the biosimilar in the US [2]. 

Teva–mAbxience
In April 2024, mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Teva Pharmaceuticals International entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.  

The Teva–mAbxience licensing agreement covers multiple global markets, including Europe and the US.

Under the terms of the licensing agreement, mAbxience will leverage its expertise in biosimilar development and its state-of-the-art, current Good Manufacturing Practice (cGMP)-approved facilities in Spain and Argentina, to develop and produce the biosimilar product. Teva will lead the regulatory processes and commercialization in the designated regions, to ensure access to a broader patient population.

This move is part of mAbxience’s global expansion strategy. It has already joined forces with Biosidus to manufacture Agalsidase Beta, a biosimilar of Fabrazyme and a treatment for Fabry disease [3]. In addition, they entered into an agreement with Abbott to commercialise biosimilars in Latin America and emerging markets [4], and with HK inno.N to bring a denosumab biosimilar to market in South Korea [2].

Related articles
Fresenius Kabi and Formycon reach agreement with J&J, Alvotech and Teva expand partnership

Similis-Blau biosimilars development partnership announced

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of aflibercept [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 5]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-aflibercept
2. GaBI Online - Generics and Biosimilars Initiative. HK inno.N–mAbxience partnership in Korea and Coherus advances in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 5]. Available from: www.gabionline.net/pharma-news/hk-inno.n-mabxience-partnership-in-korea-and-coherus-advances-in-the-us
3. GaBI Online - Generics and Biosimilars Initiative. mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 5]. Available from: www.gabionline.net/pharma-news/mabxience-and-biosidus-sign-an-agreement-to-manufacture-agalsidase-beta
4. GaBI Online - Generics and Biosimilars Initiative. Abbott and mAbxience partnership for biosimilars in emerging markets [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jun 5]. Available from: www.gabionline.net/pharma-news/abbott-and-mabxience-partnership-for-biosimilars-in-emerging-markets

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010